# Aglatimagene Besadenovec + Prodrug and Pembrolizumab vs Docetaxel for Stage IV Non-Squamous NSCLC Progressing on Pembrolizumab (AURORA)

Source: https://onco.cc/trials/aurora/  
OnCo record `aurora` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial testing Aglatimagene besadenovec in non-small-cell lung cancer, now recruiting.

## Summary

Aglatimagene Besadenovec + Prodrug and Pembrolizumab vs Docetaxel for Stage IV Non-Squamous NSCLC Progressing on Pembrolizumab (AURORA) is a phase 3 interventional study registered as NCT07660094, led by Candel Therapeutics, and recruiting on the registry. Official title: A Phase 3, Multicenter, Randomised, Controlled, Open-Label Clinical Trial of Aglatimagene Besadenovec (CAN-2409) Plus Prodrug and Pembrolizumab Versus Docetaxel for Stage IV Non-Squamous Non-Small Cell Lung Cancer Progressing on Pembrolizumab-based Treatment. Planned enrolment is 500 participants (estimated). The study started in 2026-06-15 and primary completion is expected in 2031-10-22. No results have been posted on ClinicalTrials.gov.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-11
- Also known as: AURORA
- Tags: ctgov-ingest
- Registry id: NCT07660094
- Phase: 3
- Setting: A Phase 3, Multicenter, Randomized, Controlled, Open-Label Clinical Trial of Aglatimagene Besadenovec (CAN-2409) Plus Prodrug and Pembrolizumab Versus Docetaxel for Stage IV Non-Squamous Non-Small Cell Lung Cancer Progressing on Pembrolizumab-based Treatment
- Sponsor: Candel Therapeutics
- Enrolled: 500

## Sources

- ClinicalTrials.gov NCT07660094: https://clinicaltrials.gov/study/NCT07660094

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- drugs: [Aglatimagene besadenovec](https://onco.cc/drugs/aglatimagene-besadenovec/)
- companies: [Candel Therapeutics](https://onco.cc/companies/candel-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/aurora.json